Immunofluorescent Patterns and Specificity of Human Antinuclear Antibodies

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1968 Sep 1

PMID 4973611

Citations 10

Authors

Y B BICKEL

E V Barnett

C M Pearson

Affiliations

Soon will be listed here.

Citing Articles

Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases.

Zafrir Y, Gilburd B, Garcia Carrasco M, Kivity S, Sanchez-Castanon M, Lopez-Hoyos M Immunol Res. 2013; 56(2-3):451-6.

PMID: 23579775 DOI: 10.1007/s12026-013-8416-9.

Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies.

Naot Y, Barnett E, Remington J J Clin Microbiol. 1981; 14(1):73-8.

PMID: 7021589 PMC: 271904. DOI: 10.1128/jcm.14.1.73-78.1981.

Poly(ADP-ribose) synthesis, a marker of granulocyte differentiation.

IKAI K, Ueda K, Fukushima M, Nakamura T, HAYAISHI O Proc Natl Acad Sci U S A. 1980; 77(6):3682-5.

PMID: 6997880 PMC: 349682. DOI: 10.1073/pnas.77.6.3682.

Failure to demonstrate any interaction between polyclonal rheumatoid factors and IgG antinuclear antibodies or other IgG autoantibodies.

Lloyd R Clin Exp Immunol. 1980; 41(2):297-302.

PMID: 6160005 PMC: 1537016.

False-positive anti-Toxoplasma fluorescent-antibody tests in patients with antinuclear antibodies.

Araujo F, Barnett E, Gentry L, Remington J Appl Microbiol. 1971; 22(3):270-5.

PMID: 4940868 PMC: 376297. DOI: 10.1128/am.22.3.270-275.1971.

References

Barnett E, CONDEMI J, Leddy J, Vaughan J . GAMMA-2, GAMMA-1A AND GAMMA-1M ANTINUCLEAR FACTORS IN HUMAN SERA. J Clin Invest. 1964; 43:1104-15. PMC: 289592. DOI: 10.1172/JCI104995. View

HIJMANS W, SCHUIT H, MANDEMA E, NIENHUIS R, FELTKAMP T, HOLBOROW E . COMPARATIVE STUDY FOR THE DETECTION OF ANTINUCLEAR FACTORS WITH THE FLUORESCENT ANTIBODY TECHNIQUE. Ann Rheum Dis. 1964; 23:73-7. PMC: 1030852. DOI: 10.1136/ard.23.1.73. View

ROPES M, BENNETT G, COBB S, JACOX R, JESSAR R . 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958; 9(4):175-6. View

Riggs J, SEIWALD R, BURCKHALTER J, DOWNS C, Metcalf T . Isothiocyanate compounds as fluorescent labeling agents for immune serum. Am J Pathol. 1958; 34(6):1081-97. PMC: 1934794. View

Faber V, Elling P . Leucocyte-specific anti-nuclear factors in patients with felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases. Acta Med Scand. 1966; 179(3):257-67. DOI: 10.1111/j.0954-6820.1966.tb05457.x. View

BURNHAM T, FINE G, NEBLETT T . The immunofluorescent tumor imprint technique. II. The frequency of antinuclear factors in connective tissue diseases and dermatoses. Ann Intern Med. 1966; 65(1):9-19. DOI: 10.7326/0003-4819-65-1-9. View

Willkens R, Decker J . RHEUMATOID ARTHRITIS WITH SEROLOGIC EVIDENCE SUGGESTING SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL, SEROLOGIC AND CHROMATOGRAPHIC STUDIES. Arthritis Rheum. 1963; 6:720-35. DOI: 10.1002/art.1780060607. View

Barnett E . Antinuclear antibodies and nuclear antigens. Calif Med. 1966; 104(6):463-9. PMC: 1516292. View

Barnett E, Bakemeier R, Leddy J, Vaughan J . HETEROGENEITY OF ANTINUCLEAR FACTORS IN LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS. Proc Soc Exp Biol Med. 1965; 118:803-6. DOI: 10.3181/00379727-118-29976. View

10.

Klein W, Beiser S, Erlanger B . Nuclear fluorescence employing antinucleoside immunoglobulins. J Exp Med. 1967; 125(1):61-70. PMC: 2138338. DOI: 10.1084/jem.125.1.61. View

11.

BECK J . Variations in the morphological patterns of "autoimmune" nuclear fluorescence. Lancet. 1961; 1(7188):1203-5. DOI: 10.1016/s0140-6736(61)91944-4. View

12.

BROOKS G, COBB S . Studies in latex agglutination: an approach to the determination of optimum conditions for discrimination between rheumatoids and normals. Arthritis Rheum. 1963; 6:198-207. DOI: 10.1002/art.1780060303. View

13.

Wasserman E, Levine L . Quantitative micro-complement fixation and its use in the study of antigenic structure by specific antigen-antibody inhibition. J Immunol. 1961; 87:290-5. View

14.

Bravo J, Herman J, SMYTH C . Musculoskeletal disorders after renal homotransplantation. A clinical and laboratory analysis of 60 cases. Ann Intern Med. 1967; 66(1):87-104. DOI: 10.7326/0003-4819-66-1-87. View

15.

HASKER J, Mackay I, MILLER 3rd J . THE INCIDENCE OF "ANTINUCLEAR FACTOR" IN HUMAN DISEASE. Australas Ann Med. 1965; 14:96-101. DOI: 10.1111/imj.1965.14.2.96. View

16.

BARDAWIL W, TOY B, GALINS N, BAYLES T . Disseminated lupus erythematosus, scleroderma, and dermatomyositis as manifestations of sensitization to DNA-protein. I. An immunohistochemical approach. Am J Pathol. 1958; 34(4):607-29. PMC: 1934771. View

17.

Tan E . Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus. J Lab Clin Med. 1967; 70(5):800-12. View

18.

CASALS S, Friou G, Teague P . SPECIFIC NUCLEAR REACTION PATTERN OF ANTIBODY TO DNA IN LUPUS ERYTHEMATOSUS SERA. J Lab Clin Med. 1963; 62:625-31. View

19.

Tan E, KUNKEL H . Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol. 1966; 96(3):464-71. View

20.

BEUTNER E, HOLBOROW E, JOHNSON G . A new fluorescent antibody method: mixed antiglobulin immunofluorescence or labelled antigen indirect immunofluorescence staining. Nature. 1965; 208(5008):353-5. DOI: 10.1038/208353a0. View